

Date: May 13, 2025

To  
The Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai – 400001  
Scrip Code: 543064

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400051  
Scrip Symbol: SUVENPHAR

**Sub: Change in the name and trading symbol – Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

Dear Sir/ Madam,

This is further and in continuation to our disclosure dated May 7, 2025, informing that the Ministry of Corporate Affairs, Government of India, has approved the change of name of the Company from “**Suven Pharmaceuticals Limited**” to “**Cohance Lifesciences Limited**”, with effect from May 7, 2025.

In this connection, we further would like to update that pursuant to the approvals of the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE), *vide* their letter/ notice both dated May 13, 2025, **effective from May 19, 2025**, the shares of the Company shall be traded on NSE & BSE in its new name. The details are as under:

	Old name and symbol	New name and symbol
<b>Name of the Company</b>	Suven Pharmaceuticals Limited	<b>Cohance Lifesciences Limited</b>
<b>BSE Scrip Code</b>	543064	<b>543064</b>
<b>NSE Symbol</b>	SUVENPHAR	<b>COHANCE</b>

The NSE and BSE letter/ notice dated May 13, 2025 are annexed herewith for reference.

We request to take the aforesaid disclosure on your records.

Thanking you.

Yours faithfully,  
For **Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

**Kundan Kumar Jha**  
*Company Secretary, Compliance Officer and Head-Legal*

Encl: as above

**Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad  
Knowledge City, TSIC, Raidurg, Hyderabad – 500081, Telangana, India.  
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,  
Chakala, Andheri East, Chakala MIDC, Mumbai – 400093, Maharashtra, India.  
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | Company Email: [info@suvenpharm.com](mailto:info@suvenpharm.com)





Ref: NSE/LIST/340

May 13, 2025

To,  
**The Company Secretary**  
**Suven Pharmaceuticals Limited**  
215 Atrium, C Wing, 8th Floor, 819-821,  
Andheri Kurla Road, Chakala, Andheri East,  
Chakala MIDC, Mumbai – 400093, Maharashtra

**Kind Attention: Mr. Kundan Kumar Jha**

**Subject: Change in the Name and Symbol of the Company**

Dear Sir,

This is with reference to your application for change in name and symbol of the Company.

It is hereby informed that application of the Company has been considered and approved by the Exchange.

We have taken note of the same and consequently the name and the symbol of the Company would be changed and effective in our master records **w.e.f. May 19, 2025** as follows:

Sr. No	Existing Symbol	New Symbol	Existing Name	New Name
1	SUVENPHAR	COHANCE	Suven Pharmaceuticals Limited	Cohance Lifesciences Limited

Yours faithfully,  
**For National Stock Exchange of India Limited**

**Rachna Jha**  
**Manager**

## NOTICES

Notice No. 20250513-44 Notice Date 13 May 2025  
Category Corporate Actions Segment Equity  
Subject Change in Name of the Company  
Attachments [COI.pdf](#) ;  
Content

Trading Members of the Exchange are hereby informed that the under-mentioned Company has informed the Exchange about the Change in Name of the Company. Accordingly, the SCRIP ID and ABBREVIATED NAME of the Company for BOLT Plus SYSTEM will be changed as follows w.e.f May 19, 2025 :-

Scrip Code	Existing Name	New Name	Scrip ID for BOLT Plus System*	Abbreviated name on BOLT Plus System*
543064	Suven Pharmaceuticals Ltd	Cohance Lifesciences Limited	COHANCE	COHANCE
143064	Suven Pharmaceuticals Ltd	Cohance Lifesciences Limited	COHANCE#	COHANCE#

**Marian Dsouza**

**Senior Manager - Listing Operations (CRD)**

**May 13, 2025**